1
|
Ye W, Leng C, Chen J, Mai Z, Liu N, Zhang S, Fu J, Liu Q. Characteristics analyses and tumor staging proposal for primary malignant melanoma of the esophagus: a retrospective study. Dis Esophagus 2025; 38:doaf009. [PMID: 39970075 DOI: 10.1093/dote/doaf009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/15/2024] [Revised: 01/17/2025] [Accepted: 02/05/2025] [Indexed: 02/21/2025]
Abstract
Primary malignant melanoma of the esophagus (PMME) is a malignant tumor with a poor prognosis. This study aimed to conduct survival analysis for patients with PMME and propose a staging system for PMME. Data from 179 patients were compiled for survival analysis and to propose a staging system for PMME. Survival analysis was conducted using the Kaplan-Meier method, log-rank test, and Cox proportional hazards model. The median OS of the 179 patients with PMME was 20.0 months. The 1-, 3-, and 5-year survival rates were 67.0%, 35.0%, and 17.0%. In the pooled analysis of 179 patients, significant differences in OS were observed between patients with tumors invading the lamina propria or muscularis mucosae (T1a) and deeper layers (T1b, T2, T3, T4) (P < 0.001). Significant differences in OS were observed between patients with no regional lymph node metastasis and those with one or more regional lymph node metastases (P < 0.001). PD-1 inhibitors significantly improved 3-year OS for patients with the pT1b-4 N+ stage (P = 0.020). The proposed staging system for PMME is as follows: (1) Stage I: T1aN0M0 (2) Stage II: T1b-4N0M0 and T1N1M0; Stage III: T2-4N1M0 and TxNxM1(P < 0.001). The lower T-stage and no lymph node metastasis indicated better prognosis. Surgery could be considered an effective treatment for patients with early-stage PMME. The effectiveness of surgery as a treatment for advanced-stage patients remained unclear and required further research. However, PD-1 inhibitors might improve the 3-year OS for advanced-stage patients. Furthermore, the tumor, node, metastasis staging system for PMME was proposed, and could be valuable in guiding prognostic predictions.
Collapse
Affiliation(s)
- Weijie Ye
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Esophageal Cancer Institute, Guangzhou City, China
| | - Changsen Leng
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Esophageal Cancer Institute, Guangzhou City, China
| | - Junying Chen
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Esophageal Cancer Institute, Guangzhou City, China
| | - Zihang Mai
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Esophageal Cancer Institute, Guangzhou City, China
| | - Nianjin Liu
- Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou City, China
| | - Shuishen Zhang
- Department of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China
| | - Jianhua Fu
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Esophageal Cancer Institute, Guangzhou City, China
| | - Qianwen Liu
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Esophageal Cancer Institute, Guangzhou City, China
| |
Collapse
|
2
|
Zhu ML, Wang LY, Bai XQ, Wu C, Liu XY. Primary malignant melanoma of the esophagus combined with squamous cell carcinoma: A case report. World J Gastrointest Surg 2023; 15:287-293. [PMID: 36896304 PMCID: PMC9988636 DOI: 10.4240/wjgs.v15.i2.287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2022] [Revised: 12/13/2022] [Accepted: 01/10/2023] [Indexed: 02/27/2023] Open
Abstract
BACKGROUND Primary malignant melanoma of the esophagus is a rare malignant tumor of the esophagus, and its combination with squamous cell carcinoma is also rare. Here, we report the diagnosis and treatment of a case of primary esophageal malignant melanoma combined with squamous cell carcinoma.
CASE SUMMARY A middle-aged man underwent gastroscopy for dysphagia. Gastroscopy revealed multiple bulging esophageal lesions, and after pathologic and immunohistochemical analyses, the patient was finally diagnosed with "malignant melanoma with squamous cell carcinoma". This patient received comprehensive treatment. After one year of follow-up, the patient was in good condition, and the esophageal lesions seen on gastroscopy were controlled, but unfortunately, liver metastasis occurred.
CONCLUSION When multiple esophageal lesions are present, the possibility of multiple pathological sources should be considered. This patient was diagnosed with primary esophageal malignant melanoma combined with squamous cell carcinoma.
Collapse
Affiliation(s)
- Mei-Lin Zhu
- Department of Geriatrics, Jining No. 1 People's Hospital, Jining 272000, Sahndong Province, China
| | - Ling-Yun Wang
- Department of Gastroenterology, Jining No. 1 People's Hospital, Jining 272000, Shandong Province, China
| | - Xue-Qin Bai
- Department of Pathology, Jining No. 1 People's Hospital, Jining 272000, Sahndong Province, China
| | - Chen Wu
- Department of Gastroenterology, Jining No. 1 People's Hospital, Jining 272000, Shandong Province, China
- College of Clinical Medicine, Jining Medical University, Jining 272013, Shandong Province, China
| | - Xiang-Yu Liu
- Department of Gastroenterology, Jining No. 1 People's Hospital, Jining 272000, Shandong Province, China
| |
Collapse
|